Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Angiopoietin-1 is required for Schlemm’s canal development in mice and humans
Benjamin R. Thomson, … , Terri L. Young, Susan E. Quaggin
Benjamin R. Thomson, … , Terri L. Young, Susan E. Quaggin
Published November 6, 2017
Citation Information: J Clin Invest. 2017;127(12):4421-4436. https://doi.org/10.1172/JCI95545.
View: Text | PDF
Research Article Ophthalmology Vascular biology

Angiopoietin-1 is required for Schlemm’s canal development in mice and humans

  • Text
  • PDF
Abstract

Primary congenital glaucoma (PCG) is a leading cause of blindness in children worldwide and is caused by developmental defects in 2 aqueous humor outflow structures, Schlemm’s canal (SC) and the trabecular meshwork. We previously identified loss-of-function mutations in the angiopoietin (ANGPT) receptor TEK in families with PCG and showed that ANGPT/TEK signaling is essential for SC development. Here, we describe roles for the major ANGPT ligands in the development of the aqueous outflow pathway. We determined that ANGPT1 is essential for SC development, and that Angpt1-knockout mice form a severely hypomorphic canal with elevated intraocular pressure. By contrast, ANGPT2 was dispensable, although mice deficient in both Angpt1 and Angpt2 completely lacked SC, indicating that ANGPT2 compensates for the loss of ANGPT1. In addition, we identified 3 human subjects with rare ANGPT1 variants within an international cohort of 284 PCG patients. Loss of function in 2 of the 3 patient alleles was observed by functional analysis of ANGPT1 variants in a combined in silico, in vitro, and in vivo approach, supporting a causative role for ANGPT1 in disease. By linking ANGPT1 with PCG, these results highlight the importance of ANGPT/TEK signaling in glaucoma pathogenesis and identify a candidate target for therapeutic development.

Authors

Benjamin R. Thomson, Tomokazu Souma, Stuart W. Tompson, Tuncer Onay, Krishnakumar Kizhatil, Owen M. Siggs, Liang Feng, Kristina N. Whisenhunt, Tammy L. Yanovitch, Luba Kalaydjieva, Dimitar N. Azmanov, Simone Finzi, Christine E. Tanna, Alex W. Hewitt, David A. Mackey, Yasmin S. Bradfield, Emmanuelle Souzeau, Shari Javadiyan, Janey L. Wiggs, Francesca Pasutto, Xiaorong Liu, Simon W.M. John, Jamie E. Craig, Jing Jin, Terri L. Young, Susan E. Quaggin

×

Figure 6

Expression and multimerization pattern of ANGPT1 variants.

Options: View larger image (or click on image) Download as PowerPoint
Expression and multimerization pattern of ANGPT1 variants.
(A) Western b...
(A) Western blot of FLAG-tagged WT and variant ANGPT1 proteins secreted by transfected HEK293 cells. Under nonreducing conditions WT and ANGPT1K249R (K249R-FLAG) were observed in high-order oligomers. The premature stop codon upstream of the FLAG tag in ANGPT1Q236* (Q236*-FLAG) prevented production of full-length, FLAG-tagged protein. Surprisingly, however, despite the insertion of the FLAG tag upstream of the premature stop codon in ANGPT1R494* (R494_F498del-FLAG), no tagged protein was detected in the culture medium. (B) Western blot of HUVECs incubated with conditioned media from transfected HEK293 cells. Conditioned media from cells expressing WT ANGPT1 and ANGPT1K249R strongly induced AKT phosphorylation, while media from cells expressing ANGPT1Q236* and ANGPT1R494* did not. (C) Conditioned medium from HEK293 cells transfected with WT ANGPT1-FLAG or ANGPTK249R-FLAG was incubated with recombinant human TEK-Fc fusion protein to test the receptor-binding ability of this variant protein. (D) When coexpressed, FLAG-tagged WT ANGPT1 strongly pulled down ANGPT1Q236* with an HA tag inserted upstream of the premature stop codon (Q236_F498del-HA), indicating an interaction and potential dominant-negative activity. (E and F) Untagged WT and R494* variant ANGPT1 was expressed in HEK293 cells and immunoblotted using anti-ANGPT1 antibody. Only WT protein was detected in the conditioned medium, while ANGPT1R494* appears to be expressed but retained in the intracellular compartment. MG132 treatment was performed to block the proteasomal pathway. Coomassie blue staining and anti-tubulin (Tub) immunoblotting were used as loading controls for the conditioned media and cell lysate, respectively.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts